Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6424783 | PMC |
| http://dx.doi.org/10.21037/jtd.2018.12.90 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Eliminating the 'Impossible': Recent Progress on Local Measurement Theory for Quantum Field Theory.
Found Phys
May 2024
Department of Philosophy, University of Waterloo, Waterloo, Canada.
Arguments by Sorkin (Impossible measurements on quantum fields. In: Directions in general relativity: proceedings of the 1993 International Symposium, Maryland, vol 2, pp 293-305, 1993) and Borsten et al. (Phys Rev D 104(2), 2021.
View Article and Find Full Text PDFCorrelation linking illness perception, negative emotions, and the post-operative recovery effect in patients with perianal disease.
World J Psychiatry
November 2024
Department of General Surgery, The First People's Hospital of Changde City (Changde Hospital, Xiangya School of Medicine, Central South University), Changde 415000, Hunan Province, China.
Background: Improvements in the standard of living have led to increased attention to perianal disease. Although surgical treatments are effective, the outcomes of post-operative recovery (POR) are influenced by various factors, including individual differences among patients, the characteristics of the disease itself, and the psychological state of the patient. Understanding these factors can help healthcare providers develop more personalized and effective post-operative care plans for patients with perianal disease.
View Article and Find Full Text PDFObjective: Virtually anything can be ranked; the (USNWR or US News) ranks the top 50 hospitals specializing in cardiology, heart, and vascular surgery. Here the authors propose validating the effectiveness of rankings by comparing differences among the USNWR metrics across the top 50 hospitals.
Methods: The ranking system for the top 50 hospitals specializing in cardiology, heart, and vascular surgery was derived from 16 variant scores.
Prognostic and Predictive Value of a Modified Diagnostic Biopsy-Adapted Immunoscore in Patients with Rectal Cancer After Neoadjuvant Treatment: A Translational Study From the STELLAR Trial.
Int J Radiat Oncol Biol Phys
October 2024
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address:
Purpose: The purpose of this study was to assess the prognostic significance of the modified diagnostic biopsy-adapted immunoscore (mIS) in determining the outcomes for patients with locally advanced rectal cancer (LARC) in a neoadjuvant setting.
Methods And Materials: We included 181 patients with LARC from a single subcenter of a prospective study comparing total neoadjuvant therapy (TNT) based on short-course radiation therapy with long-term chemoradiation therapy (CRT). Tumor biopsies at baseline were stained for CD8+ and CD3+ T-cell densities.
Case report: Conjunctival melanoma treated with relatlimab and nivolumab showing remarkable response.
Front Oncol
September 2024
Department of Oncology, Emek Medical Center, Afula, Israel.
Article Synopsis
- Conjunctival melanoma, a rare type of ocular melanoma, has some genetic similarities to both skin and mucosal melanoma and presents unique treatment challenges when advanced or metastatic.
- The FDA recently approved the combination treatment Nivolumab/relatlimab (Opdualag) for metastatic melanoma, showing improved survival rates in earlier treatment stages without significant safety concerns, but its effectiveness in conjunctival melanoma is still unknown.
- In a case study, an 87-year-old woman with advanced conjunctival melanoma showed a near-complete clinical response after just one cycle of Opdualag, although treatment was limited to four cycles due to her worsening dementia.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!